Author

Huisi Liu

Institution: Innovent Biologics (China)

Observed institutions: National Institute of Biological Sciences, Beijing, Innovent Biologics (China)

ORCID: 0009-0003-2749-3343

Observed ORCID: 0009-0003-2749-3343

OpenAlex ID: A5090067222

IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells

2023 · Weiwei Wu, Tiongsun Chia, et al. · Nature Cancer · 87

Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8+ T cells and inhibited tumor growth

2024 · Xueyuan Lyu, Linlin Zhao, et al. · Journal for ImmunoTherapy of Cancer · 10

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity

2022 · Huisi Liu, Weiwei Wu, et al. · Cell Reports Medicine · 6

The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity

2026 · Jia Liu, Jingbo Ma, et al. · Cancer Research

Abstract 4249: IBI3019, a first-in-class EGFR/CDH17/CD16A tri-specific antibody, demonstrated potent efficacy against CRC and an excellent safety profile in preclinical studies

2025 · Tiongsun Chia, Weiwei Wu, et al. · Cancer Research

Works count: 5

Citation count: 103

H-index: 3

I10-index: 2